Cometriq Approval History

  • FDA approved: Yes (First approved November 29th, 2012)
  • Brand name: Cometriq
  • Generic name: cabozantinib
  • Company: Exelixis, Inc.
  • Treatment for: Thyroid Cancer

Cometriq (cabozantinib) is a kinase inhibitor indicated for the treatment of patients with progressive, metastatic medullary thyroid cancer.

FDA Approval History for Cometriq

DateArticle
Nov 29, 2012Approval FDA Approves Cometriq (cabozantinib) to Treat Rare Type of Thyroid Cancer
Aug 30, 2012Exelixis Provides Update on ODAC Panel for Cabozantinib
Jul 30, 2012FDA Grants Priority Review for Cabozantinib in Medullary Thyroid Cancer
May 30, 2012Exelixis Completes Submission of New Drug Application for Cabozantinib for the Treatment of Medullary Thyroid Cancer

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Advanced Breast Cancer: Learn about treatments to improve quality of life. Click Here

Close
Hide
(web1)